ClinicalTrials.gg
CompletedNCT02176876Updated Jun 29, 2015

Safety, Tolerability, and Pharmacokinetics of GS-5745 in Subjects With Rheumatoid Arthritis

A Phase 1 interventional study of GS-5745 and Placebo to match GS-5745 in Rheumatoid Arthritis, sponsored by Gilead Sciences. Completed at 4 sites in 2 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2015-06-29.

Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
18
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Arthritis, Rheumatoid by Gilead Sciences — none open to participants now, 1 under way, none of them phase 3. Arthritis, Rheumatoid · Gilead Sciences.

Enrollment
10th of 12
18 · median 49
Started
2014
the only one that year
Phase 1
6 of 12
none open now
Registered
1st of 12
by date

Among the 12 studies in Arthritis, Rheumatoid by Gilead Sciences, this one is the 10th largest by enrollment, is the only one that started in 2014, is one of 6 in phase 1, and was the 1st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

None of the 12 studies in Arthritis, Rheumatoid by Gilead Sciences is open now. The open studies under Arthritis, Rheumatoid, anywhere →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Arthritis, Rheumatoid by Gilead Sciences as a file.
02

Study summary

This study is to assess the safety, tolerability, and pharmacokinetics (PK) of multiple infusions of GS-5745 in adults with rheumatoid arthritis (RA). Participants will be randomized in a 4:1 ratio to receive 1 intravenous (IV) infusion of GS-5745 or placebo every 2 weeks, for a total of 3 IV infusions.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • rheumatoid arthritis
  • RA
  • GS-5745
  • MMP9
  • phase 1
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 70 years of age, inclusive, at time of screening
  • Weight: ≥ 45 to \< 120 kg
  • Males or non-pregnant, non-lactating females
  • Diagnosis of RA according to the 1987 revised American College of Rheumatology (ACR) for the classification of RA
  • Active disease, defined as a mean high sensitivity C-reactive protein (hsCRP) value from Visits 1 \& 2 of ≥ 8 mg/L
  • Individuals taking chronic Disease-Modifying Antirheumatic Drugs (DMARDs) should be on a stable dose for at least 45 days prior to randomization
  • Chronic use of systemic up to a maximum of 10 mg/day of prednisone or equivalent is allowed if dose is stable for at least 30 days prior to randomization
  • Nonsteroidal Anti-inflammatory Drugs (NSAIDs) or other analgesics are allowed if doses are stable for at least 30 days prior to randomization

Exclusion criteria

Exclusion Criteria:

  • Have a document medical history of anaphylaxis
  • Positive antibody during screening
  • Positive surface antigen (HBsAg), or positive hepatitis B core antigen (HBcAg), followed by a positive hepatitis B virus (HBV) DNA by quantitative polymerase chain reaction (PCR) during screening
  • Positive virus (HCV) antibody followed by a positive HCV viral RNA during screening
  • A positive QuantiFERON-tuberculosis (TB) GOLD test during screening
  • History of within the last 5 years except for individuals who have been treated locally for non-melanoma skin cancer or cervical carcinoma in situ
  • Severe dementia or Alzheimer's disease, chronic medical or psychiatric problem, or alcohol or drug abuse, that in the judgment of the investigator may interfere with individual's ability to comply with study procedures
  • Any serious cardiac event such as myocardial infarction, unstable or life-threatening arrhythmia, hospitalization for cardiac failure within 6 months prior to randomization or any significant or new finding at Visit 1 as judged by the investigator
  • History of significant systemic involvement secondary to RA such as vasculitis, pulmonary fibrosis, or Felty's syndrome
  • History of or current inflammatory joint disease, other than RA, such as gout, reactive arthritis, psoriatic arthritis, seronegative spondylarthritis, or Lyme disease
  • History of or current or rheumatic disorders, other than RA, such as systemic lupus erythematosus, inflammatory bowel disease, fibromyalgia, polymyalgia rheumatic, scleroderma, inflammatory myopathy, mixed connective tissue disease, or other overlap syndrome
  • Any chronic medical condition (including, but not limited to, cardiac or pulmonary disease) that, in the judgment of the investigator, would make the individual unsuitable for the study or would prevent compliance with the study protocol
  • Treatment with antibiotics for a clinical infection or other medical condition within 30 days prior to randomization
  • Treatment with azathioprine or cyclosporine 90 days prior to randomization
  • Treatment with infliximab, golimumab, adalimumab, abatacept, tocilizumab within 90 days; and etanercept or anakinra within 30 days of randomization
  • Treatment with rituximab or any B-cell depleting agent within 12 months of randomization
  • Treatment with any other marketed or biologic within 5 half-lives of the molecule or if unknown within 90 days of randomization
  • Administration of any investigational drug or use of any investigational device within 30 days prior to randomization
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
18 participants (actual)

Study arms

  • Experimental
    GS-5745

    Participants will receive GS-5745 every 2 weeks for a total of 3 infusions.

    Drug: GS-5745

  • Placebo comparator
    Placebo to match GS-5745

    Participants will receive placebo to match GS-5745 every 2 weeks for a total of 3 infusions.

    Drug: Placebo to match GS-5745

Interventions

  • GS-5745 400 mg administered intravenously

  • DrugPlacebo to match GS-5745

    Placebo to match GS-5745 administered intravenously

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events, changes in laboratory tests and vital signs from baseline, and development of immunogenicity after dosing

    This composite endpoint will measure the safety and tolerability profile of GS-5745.

    Time frame: Up to 100 days

Secondary outcomes

  1. PK profile of GS-5745

    This composite endpoint will measure the plasma PK profile of GS-5745. The following parameters will be measured, where applicable: * Cmax: maximum observed concentration of drug in plasma * Tmax: time of Cmax * Clast: last observable concentration of drug * Tlast: time of Clast * AUClast: concentration of drug from time zero to the last quantifiable concentration * AUCinf: concentration of drug extrapolated to infinite time (area under the plasma concentration versus time curve extrapolated to infinite time) * AUCtau: concentration of drug over time (area under the plasma concentration versus time curve over the dosing interval) * Ctau: observed drug concentration at the end of the dosing interval * λz: terminal elimination rate constant * CL: systemic clearance of the drug following intravenous administration * Vz: volume of distribution of the drug following intravenous administration

    Time frame: Pre-infusion, 30 minutes, 4 hours, and 24 hours post-infusion on Day 1; pre-infusion and 30 minutes post-infusion on Days 15 and 29; Days 4, 8, 36, and 43

07

Study locations

4 sites
  • Praha, Czech Republic
  • Balatonfured, Veszprem, Hungary
  • Budapest, Hungary
  • Debrecen, Hungary
08

References and documents

Publications

  • Gossage DL, Cieslarova B, Ap S, Zheng H, Xin Y, Lal P, Chen G, Smith V, Sundy JS. Phase 1b Study of the Safety, Pharmacokinetics, and Disease-related Outcomes of the Matrix Metalloproteinase-9 Inhibitor Andecaliximab in Patients With Rheumatoid Arthritis. Clin Ther. 2018 Jan;40(1):156-165.e5. doi: 10.1016/j.clinthera.2017.11.011. Epub 2017 Dec 26. PubMed 29287749 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2014, a primary completion of Apr 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 25, 2014
First posted
Jun 27, 2014
Start
Aug 2014
Primary completionActual
Apr 2015
CompletionActual
Jun 2015
Last update
Jun 29, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02176876
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Jun 27, 2014
Start date
Aug 2014
Primary completion
Apr 2015
Completion
Jun 2015
Last update
Jun 29, 2015

Study contacts

David Gossage, MD
study director · Gilead Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Andecaliximab

Start the discussion